Sarah Cooleybeck

Apr 3, 2024 | mondaq.com | Brian Carey |Sarah Cooleybeck |Shrutih Tewarie |Patrick Brennan

Bipartisan legislation moving through the U.S. House and Senate, known as the BIOSECURE Act, could limit the ability of U.S. life sciences companies to contract with biotechnology companies with ties to the Chinese government or another "foreign adversary." The potentially broad scope of the legislation would both prohibit the U.S. government from contracting with a "biotechnology company of concern," as well as prevent companies that contract with or receive funding from the federal...

Mar 28, 2024 | jdsupra.com | Patrick Brennan |Brian Carey |Sarah Cooleybeck

Key Takeaways: Bipartisan legislation moving through the U.S. House and Senate, known as the BIOSECURE Act, could limit the ability of U.S. life sciences companies to contract with biotechnology companies with ties to the Chinese government or another “foreign adversary.” The potentially broad scope of the legislation would both prohibit the U.S. government from contracting with a “biotechnology company of concern,” as well as prevent companies that contract with or receive funding from the...